Table 2. Effects of vitamin D supplementation on changes of nitric oxide, inflammation, and fibrotic biomarkers.
| Baseline | Follow-up | p-value | |
|---|---|---|---|
| TSP-1 (ng/mL) ** | 535.0 (39.0, 2734.0) | 134.5 (26.7, 894.2) | <0.001 |
| ADMA (μmol/L) | 0.56 ± 0.09 | 0.57 ± 0.08 | 0.6 |
| L-arginine (μmol/L) | 94.8 ±18.1 | 97.1 ±18.5 | 0.4 |
| hs-CRP (mg/L) ** | 1.8 (0.33, 27) | 1.8 (0.32, 19) | 0.9 |
| PAI-1 (ng/mL) | 1192.7±797 | 1198.3±855 | 0.9 |
| Activin-A (pg/mL) | 210.3±72 | 211.6±69 | 0.9 |
| FSTL-3 (pg/mL) | 5927.9±1428 | 5891.9±1194.2 | 0.8 |
| Inhibition of platelet aggregation by SNP (%) | 18.6 (0, 85) | 15.4 (0, 87) | 0.1 |
| ADP-induced platelet aggregation (Ω) | 8.2±1.9 | 8.5±2.2 | 0.5 |
ADMA = asymmetric dimethylarginine; hs-CRP = hs-C-reactive protein; TSP-1 = thrombospondin-1; SNP = sodium nitroprusside
** Non-normally distributed data are expressed as median (min, max).